Gregory Daniel
Vice President, Head of Public Policy Innovation, Evidence, and Engagement
Washington DC-Baltimore Area · 1 connectionNot on Unlinked · Imported profile. Is this you? Claim it
Is this about you? Request removal
About
Executive leader in health policy, pharmaceutical & medical device policy, and real-world evidence (RWE) development with leadership experience in the CRO/payer, academic, DC-based think-tank and life sciences corporate environments. Dedicated to advancing policies that encourage and support high-value breakthrough innovation that meets patient unmet needs and, at the same time, enable equal and affordable access to such treatments. Global Head of Public Policy at Eli Lilly and Company; Editor-in-Chief, Therapeutic Innovation and Regulatory Science (TIRS) peer-reviewed scientific journal; and Past-President, Board of Directors, Innovation in Value Initiative (IVI). Policy expertise: ♦ Drug and medical device payment and coverage policy ♦ Value-based healthcare reforms ♦ Regulatory science, drug/device development policy ♦ Improving the use of real-world evidence (RWE) to support regulatory and payer decisions. Data and research expertise: ♦ RWE, health economics and outcomes research, comparative effectiveness research, and drug safety and pharmacoepidemiology ♦ Biostatistics and epidemiology ♦ Leveraging real world data from health insurance claims and EHRs to support research tha
Experience
Jan 2024
Jan 2016 to Aug 2019
Education
Doctor of Philosophy Pharmaceutical Economics Policy and Outcomes
2004 to 2008
Master of Public Health Biostatistics
2000 to 2002
Master of Science Pharmaceutcial Sciences
2000 to 2002
Bachelor of Science Pharmacy
1995 to 2000